Our ESG reporting is updated regularly aligned with our transparency polices, practices, and data

Our ESG reporting is updated regularly aligned with our transparency polices, practices, and data.

Sustainability Disclosures | Takeda Pharmaceuticals

Divider Section

Our ESG reporting is updated regularly aligned with our transparency polices, practices, and data.

We will continuously work to improve our data capture processes and reporting of ESG information, to demonstrate our commitment to transparency and our stakeholders.





Every day, we work to ensure long-term sustainable growth, innovation and resilience. Our Annual Integrated Report outlines the progress we made in FY2023 to deliver on our purpose of better health for people and a brighter future for the world.

## 2024 Annual Integrated Report

A complete list of the metrics that supplement our Annual Integrated Report can be found in the ESG Databook.


## Takeda 2024 ESG Databook

## Downloadable index tables



[Corporate philosophy metrics](http://assets-dam.ducciofiorini.com/image/upload/Global/Corporate-Responsibility/Corporate-Sustainability/Sustainability-Disclosures/2024/ESG_Metrics_en.pdf#page=4) help hold us accountable for delivering sustainable growth and building trust with our external stakeholders. Our vision is to discover and deliver life-transforming treatments, guided by our commitment to patient, people and planet. These imperatives identify where Takeda must invest to deliver on our purpose. We aim to create long-term value by aligning our actions with these imperatives and unleashing the power of data and digital. We measure our progress through our corporate philosophy metrics, disclosing results annually.
Read more about our corporate philosophy [here](/about/our-company/corporate-philosophy/).



## Corporate Philosophy Metrics

The information below provide links to our ESG disclosures under the categories of Patient, People, Planet and Values-Based Governance.  





Our approach:
<ul>
<li>[Responsibly translate science into highly innovative, life-changing medicines and vaccines](http://jvgmtt.ducciofiorini.com/about/corporate-responsibility/corporate-sustainability/sustainability-approach/sustainability-disclosures/responsibly-translate-science/)</li>
<li>[Ethics](http://jvgmtt.ducciofiorini.com/about/corporate-responsibility/ethics-disclosures/ethics/)</li>
<li>[Timely, Broad and Sustainable Access](http://jvgmtt.ducciofiorini.com/about/corporate-responsibility/corporate-sustainability/sustainability-approach/timely-broad-and-sustainable-access/)</li>
<li>[Access to Medicines](http://jvgmtt.ducciofiorini.com/about/corporate-responsibility/corporate-sustainability/access-to-medicine/)</li>
<li>[Our Commitment to Patients](http://jvgmtt.ducciofiorini.com/about/corporate-responsibility/corporate-sustainability/sustainability-approach/patients/)</li>
</ul>

Our positions:
<ul>
<li>[Our Position on Biotechnology](http://assets-dam.ducciofiorini.com/raw/upload/v1675193355/legacy-dotcom/siteassets/system/who-we-are/companyinformation/positions--guidelines/2021-takeda-position-on-biotechnology_en.pdf)</li>
<li>[Our Position on Falsified Medical Products](http://assets-dam.ducciofiorini.com/image/upload/legacy-dotcom/siteassets/system/who-we-are/companyinformation/positions--guidelines/Position_Falsified_Medical_Products.pdf)</li>
<li>[Our Position on Global Pricing](http://assets-dam.ducciofiorini.com/raw/upload/v1675193360/legacy-dotcom/siteassets/system/who-we-are/companyinformation/positions--guidelines/takeda-position-on-global-pricing-eg.pdf)</li>
<li>[Our Position on Value-Based Health Care](http://assets-dam.ducciofiorini.com/image/upload/v1684839809/legacy-dotcom/siteassets/system/who-we-are/companyinformation/positions--guidelines/Position_Value-based-Healthcare.pdf)</li>
<li>[Our Position on Health Equity](http://assets-dam.ducciofiorini.com/image/upload/Global/Corporate-Responsibility/Positions/Health_Equity.pdf)</li>
<li>[Our Position on Access to Medicines](http://assets-dam.ducciofiorini.com/image/upload/v1677028367/legacy-dotcom/siteassets/system/who-we-are/companyinformation/positions--guidelines/Position_Access_to_Medicines_New_Template.pdf)</li>
<li>[Our Position on Intellectual Property for Access to Medicines](http://assets-dam.ducciofiorini.com/raw/upload/v1675193354/legacy-dotcom/siteassets/system/who-we-are/companyinformation/positions--guidelines/2020-takeda-position-ip-for-access-to-medicine-en_final.pdf)</li>
<li>[Our Position on Data Sharing and Reuse of Health Data](http://assets-dam.ducciofiorini.com/raw/upload/v1675193360/legacy-dotcom/siteassets/system/who-we-are/companyinformation/positions--guidelines/takeda_position_data-sharing-and-reuse.pdf)</li>
</ul>

More on what we do:
<ul>
<li>[Research & Development](http://jvgmtt.ducciofiorini.com/science/research-and-development/)</li>
<li>[Alliances & Partnerships](http://jvgmtt.ducciofiorini.com/science/research-and-development/partnerships/)</li>
<li>[Areas of Focus](http://jvgmtt.ducciofiorini.com/science/areas-of-focus/)</li>
<li>[Manufacturing](http://jvgmtt.ducciofiorini.com/science/products/manufacturing/)</li>
<li>[Access to Medicines](http://jvgmtt.ducciofiorini.com/about/corporate-responsibility/corporate-sustainability/access-to-medicine/)</li>
<li>[CSR Partnerships](http://jvgmtt.ducciofiorini.com/about/corporate-responsibility/corporate-giving/programs-in-action/)</li>
<li>[Our U.S. Pricing Philosophy](http://jvgmtt.ducciofiorini.com/en-us/who-we-are/takeda-pricing-philosophy/)</li>
</ul>


## Patient



<ul>
<li>Our approach: [Talent Management](http://jvgmtt.ducciofiorini.com/about/corporate-responsibility/corporate-sustainability/sustainability-approach/talent-management/)</li>
<li>More on what we do regarding Talent recruitment and retention efforts for scientists and research and development personnel: [SASB Index Report 2024](http://assets-dam.ducciofiorini.com/image/upload/Global/Corporate-Responsibility/Corporate-Sustainability/Sustainability-Disclosures/2024/SASB_en.pdf)</li>
<li>More on who we are: [Global Environment, Health and Safety Policy](http://assets-dam.ducciofiorini.com/image/upload/v1705078449/legacy-dotcom/siteassets/system/corporate-responsibility/environment/Global_EHS_Policy_and_Position_English.pdf)</li>
</ul>

## People




Our positions:
<ul>
<li>[Our position on Climate Change](http://assets-dam.ducciofiorini.com/raw/upload/v1662721237/legacy-dotcom/siteassets/system/who-we-are/companyinformation/positions--guidelines/Takeda_Position_climate_change_2020.pdf)</li>
<li>[Our Position on Water Stewardship](http://assets-dam.ducciofiorini.com/raw/upload/legacy-dotcom/siteassets/system/who-we-are/companyinformation/positions--guidelines/position-on-water-stewardship-final-24jun22.pdf)</li>
<li>[Our Position on Biodiversity](http://assets-dam.ducciofiorini.com/image/upload/legacy-dotcom/siteassets/system/who-we-are/companyinformation/positions--guidelines/Position_Biodiversity_New_EN_Final_24MAR.pdf)</li>
<li>[Our Position on Responsible Use of Plastics](http://assets-dam.ducciofiorini.com/image/upload/legacy-dotcom/siteassets/system/who-we-are/companyinformation/positions--guidelines/Position_Plastics_New_EN_Final_24MAR.pdf)</li>
<li>[Our Position on Pharmaceuticals in the Environment](http://assets-dam.ducciofiorini.com/raw/upload/legacy-dotcom/siteassets/system/who-we-are/companyinformation/positions--guidelines/position-on-pie-final-24jun22.pdf)</li>
</ul>

Our Stories:
<ul>
<li>[Sustainable Products](http://jvgmtt.ducciofiorini.com/about/corporate-responsibility/corporate-sustainability/sustainability-approach/planet/stories/products/)</li>
<li>[Waste](http://jvgmtt.ducciofiorini.com/about/corporate-responsibility/corporate-sustainability/sustainability-approach/planet/stories/waste/)</li>
<li>[Decarbonizing](http://jvgmtt.ducciofiorini.com/about/corporate-responsibility/corporate-sustainability/sustainability-approach/planet/stories/decarbonizing/)</li>
<li>[Water](http://jvgmtt.ducciofiorini.com/about/corporate-responsibility/corporate-sustainability/sustainability-approach/planet/stories/water/)</li>
<li>[Biodiversity](http://jvgmtt.ducciofiorini.com/about/corporate-responsibility/corporate-sustainability/sustainability-approach/planet/stories/biodiversity/)</li>
</ul>

More on what we do:
<ul>
<li>Resource circularity and product take-back: [SASB Index Report 2024](http://assets-dam.ducciofiorini.com/image/upload/Global/Corporate-Responsibility/Corporate-Sustainability/Sustainability-Disclosures/2024/SASB_en.pdf)
</li> 
<li>[Our TCFD Report](http://assets-dam.ducciofiorini.com/image/upload/legacy-dotcom/siteassets/system/corporate-responsibility/environment/Takeda_2022_TCFD_Report.pdf)</li>
<li>[Our Commitment to the Planet](http://jvgmtt.ducciofiorini.com/about/corporate-responsibility/corporate-sustainability/sustainability-approach/planet/)</li>
<li>[Water Stewardship, Plastics, Biodiversity, Pharmaceuticals in the Environment and Eco-Design](http://assets-dam.ducciofiorini.com/raw/upload/v1668757019/legacy-dotcom/siteassets/system/corporate-responsibility/environment/takeda-approach-to-key-sustainability-topics.pdf)</li>
<li>[Historical Record of Takeda Voluntary Offset and EAC Purchases](http://assets-dam.ducciofiorini.com/image/upload/v1708608641/Global/Corporate-Responsibility/Corporate-Sustainability/Sustainability-Disclosures/Historical_Record_of_Takeda_Voluntary_Offset_and_EAC_Purchases.pdf)</li>
</ul>

More on who we are:
<ul>
<li>[Global Environment, Health and Safety Policy](http://assets-dam.ducciofiorini.com/image/upload/v1705078449/legacy-dotcom/siteassets/system/corporate-responsibility/environment/Global_EHS_Policy_and_Position_English.pdf)</li>
</ul>

## Planet



*   Our approach: [Corporate Governance](/about/corporate-governance/strategy)

More on who we are: 

*   [Takeda Executive Team (TET)](/about/leadership)

*   [Board of Directors](/about/board-of-directors) 

*   [Charters and Reports](/about/corporate-governance/charters-and-reports)



*   Information on Annual Shareholders Meetings, including Notices of Resolutions and Results of the Exercise of Voting Rights: [Annual Shareholders Meetings](/investors/events)

*   Information on total rewards and compensation, see [Takeda’s Executive Compensation Overview](http://assets-dam.ducciofiorini.com/raw/upload/v1662727590/legacy-dotcom/siteassets/system/investors/shareholders-meetings/sm_146_04_en.pdf) and [Corporate Governance Report](/about/corporate-governance/charters-and-reports)

Corporate Governance

*   [Our Position on Taxation](http://assets-dam.ducciofiorini.com/image/upload/v1711390793/legacy-dotcom/siteassets/system/who-we-are/companyinformation/positions--guidelines/Position_Taxation.pdf)
*   [Total taxation disclosures](http://assets-dam.ducciofiorini.com/image/upload/Global/Corporate-Responsibility/Corporate-Sustainability/Sustainability-Disclosures/tttc-en.pdf)



Taxation

*   Our approach to Quality management: [Ethics](/about/corporate-responsibility/ethics-disclosures/ethics/)

*   [Our Position on Falsified Medical Products](http://assets-dam.ducciofiorini.com/image/upload/v1684891388/legacy-dotcom/siteassets/system/who-we-are/companyinformation/positions--guidelines/Position_Falsified_Medical_Products.pdf)

*   Takeda products with safety alerts can be found in the [FDA MedWatch Safety Alerts for Human Medical Products database](http://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program)

*   Historical product recalls can be found in the [FDA Drug Recalls database](http://www.fda.gov/drugs/drug-safety-and-availability/drug-recalls?search_api_fulltext=takeda&field_terminated_recall=All)



Quality Management

*   Our approach: [Suppliers](/science/products/suppliers)

*   More on who we are: [Takeda Supplier Code of Conduct](http://assets-dam.ducciofiorini.com/raw/upload/v1675187395/legacy-dotcom/siteassets/system/what-we-do/suppliers/supplier-code-conduct/pdf/supplier-code-of-conduct-english.pdf)



Supply Chain

*   Our approach:  [Ethics ](/about/corporate-responsibility/ethics-disclosures/ethics)(including Medical Ethics, Bioethics and Human Rights)

More on who we are:

*   [Takeda Global Code of Conduct](http://assets-dam.ducciofiorini.com/raw/upload/v1675193384/legacy-dotcom/siteassets/system/who-we-are/corporate-governance/compliance/coc_digital-booklet_external.pdf)

*   [Takeda Ethics Line](http://secure.ethicspoint.com/domain/media/en/gui/28267/index.html)

*   [Takeda’s Commitment regarding Clinical Trials](http://clinicaltrials.ducciofiorini.com/takedas-commitment?commitment)

*   More about what we do on Safety of Clinical Trial Participants: [SASB Index Report 2024](http://assets-dam.ducciofiorini.com/image/upload/Global/Corporate-Responsibility/Corporate-Sustainability/Sustainability-Disclosures/2024/SASB_en.pdf)

More on our approach to human rights: 

*   [Takeda’s Human Rights Commitment](http://assets-dam.ducciofiorini.com/image/upload/v1685641724/Global/Ethics/Takeda_Human_Rights_Commitment.pdf) 

*   [Takeda UK, Australia and Canada Modern Slavery Statement for FY23](http://assets-dam.ducciofiorini.com/image/upload/v1717173034/Global/Corporate-Responsibility/Corporate-Sustainability/Sustainability-Disclosures/Takeda-UK-Australia-and-Canada-Modern-Slavery-Statement-for-FY23.pdf)

*   [Takeda AS Norway Transparency Act Report for FY23](http://assets-dam.ducciofiorini.com/image/upload/Global/Ethics/Takeda_Norway_Transparency_Act_Financial_Year_2023.pdf)

*   [Takeda Child Labor Due Diligence Report for FY23](http://assets-dam.ducciofiorini.com/image/upload/v1728001864/Global/Corporate-Responsibility/Corporate-Sustainability/Sustainability-Approach/AIR/report_on_child_labor_due_diligence.pdf)



Ethics

*   Our approach: [Risk & Crisis Management](/about/corporate-responsibility/ethics-disclosures/ethics/#ethics-across-our-business)

*   Matters related to internal controls and risk management rules: [Corporate Governance Report](/about/corporate-governance/charters-and-reports)

*   [Our Position on Public Policy Engagement](http://assets-dam.ducciofiorini.com/image/upload/v1695703484/Global/Corporate-Responsibility/Positions/takeda-position-on-public-policy-engagement_en.pdf)



Risk & Crisis Management

*   Our approach: [Corporate Giving](/about/corporate-responsibility/corporate-giving)

More about what we do:

*   [Corporate Social Responsibility Programs in Action](/about/corporate-responsibility/corporate-giving/programs-in-action)

*   [Global CSR Program Application Process](/about/corporate-responsibility/funding)



Philanthropy (Global CSR)

## Values-based governance



Position papers stating our approach towards specific topics

## Explore



Sustainability Disclosures

Cancel

Links to sites outside of ducciofiorini.com are provided as a resource to the audiences. Please note that Takeda is not responsible or liable for any third-party website and the website may not be appropriate for all audiences. 

To stay on the current website, select “Cancel”
